Sanofi

SanofiSanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

www.sanofi.com

Filters
List of articles in category Sanofi
Title Published Date
Sanofi and Lead Pharma to develop treatments for autoimmune diseases 18 February 2015
Curie-Cancer and Sanofi cooperate in research on ovarian cancer 20 June 2013
Sanofi strengthens its French-German partnership 16 April 2013
Once-daily Lyxumia® (lixisenatide) approved for treatment of type 2 diabetes 04 February 2013
Sanofi provides information on the adaptation of its activities in France through 2015 25 September 2012
Sanofi and the Institut Pasteur create four prestigious awards 27 February 2012
Sanofi fourth-quarter and full-year net sales 08 February 2012
Genzyme Announces European Approval of Framingham Manufacturing Plant 17 January 2012
Sanofi net sales up 10.1% and Business net income up 4.1% at CER 03 November 2011
Findings from Two-Year Pivotal Phase III TEMSO Trial 07 October 2011
Lixisenatide Significantly Reduces HbA1c Without Increasing Hypoglycemia in Patients Uncontrolled on Sulfonylureas 14 April 2011
Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation 06 April 2011
Sanofi-aventis Strengthens Commitment to Ophthalmology through Partnership with The Vision Institute 24 March 2011
Sanofi Pasteur and International Vaccine Institute Partner against Dengue 23 February 2011
Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right 17 February 2011
European Commission Clears Acquisition of Genzyme Corporation by sanofi-aventis 17 January 2011
Sanofi-aventis Establishes Research Collaboration with Harvard University 20 October 2010
Sanofi-aventis Initiates 10,000 Patient Study with Multaq® in Permanent Atrial Fibrillation 13 May 2010
Sanofi-aventis and CureDM Sign Exclusive Worldwide License Agreement on Novel Regenerative Compound to Treat Diabetes 08 April 2010
AgaMatrix and sanofi-aventis Enter Global Diabetes Partnership 01 April 2010